Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Titel:
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Auteur:
Weisel, Katja Krishnan, Amrita Schecter, Jordan M. Vogel, Martin Jackson, Carolyn C. Deraedt, William Yeh, Tzu-min Banerjee, Arnob Yalniz, Fevzi Nesheiwat, Tonia Van Sanden, Suzy Diels, Joris Valluri, Satish Usmani, Saad Z. Berdeja, Jesus G. Jagannath, Sundar Martin, Tom